AKT1 and breast carcinoma: For instance, the PIK3CA Q859 and W780 mutations, and AKT E17K/Q79K mutations, confer resistance to inavolisib and alpelisib in breast cancer patients with baseline PIK3CA mutations (H1047R, E542K/E545K) [35].